• AGE Inhibitor
• Brain Support
• Thiamin Deficiency
Serving Size: 2 Capsules... %DV
Benfotiamine... 160 mg... †
† Daily Value not established
What Is It?
Vitamin B1, also known as thiamin, was the first vitamin to be discovered. It was also the first time the word vitamin, which literally means "essential to life", was used. Benfotiamine has proven to be 5 times more absorbable than thiamin and has better penetration through cellular membranes.
What Does It Do?
Primary Uses: Benfotiamine prevents protein glycation (known as the formation of Advanced Glycation End-products or AGEs), a role that is not shared by thiamin. The formation of AGEs is exacerbated by high blood sugar and leads to significant tissue dysfunction, disrupts protein structures, damages DNA, and speeds up the aging process, such as is seen in diabetics suffering from nerve damage in the limbs, heart, eyes, etc. Benfotiamine may help reduce nerve pain due to hyperglycemia and may improve nerve function.
Who Should Take It?
With our modern high-sugar diet, millions are experiencing the many negative effects that excessive sugar has on the body. Those looking for protection against these negative effects such as accelerated cellular aging and nerve damage should consider benfotiamine.
Start with 2 capsules twice daily with food for the first month; you may then continue at this dose or reduce to 2 capsules daily, or as directed by a qualified health care practitioner.
Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D, Neumaier M, Bergfeld R, Giardino I, Brownlee M. “Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy.”
Nat Med. 2003 Mar; 9(3): 294-9.
Koltai MZ. “Prevention of cardiac autonomic neuropathy in dogs with Benfotiamine.”
In Gries FA, Federlin K. “
Benfotiamine in the Therapy of Polyneuropathy.”
New York: Georg Thieme Verlag, 1998; 45-9.
Lin J, Alt A, Liersch J, Bretzel RG, Brownlee MA, Hammes HP. “
Benfotiamine inhibits intracellular formation of advanced glycation endproducts in vivo.”
Diabetes. 2000 May; 49(Suppl1): A143 (P583).
Loew D. “
Pharmacokinetics of thiamine derivatives especially of Benfotiamine.”
Int J Clin Pharmacol Ther. 1996 Feb; 34(2): 47-50.
Stracke H, Lindemann A, Federlin K. “
A Benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy.”
Exp Clin Endocrinol Diabetes 1996; 104(4): 311-6.
Winkler G, Pal B, Nagybeganyi E, Ory I, Porochnavec M, Kempler P. “
Effectiveness of different Benfotiamine dosage regimens in the treatment of painful diabetic neuropathy.”
Arzneimittelforschung. 1999 Mar; 49(3): 220-4.
Disclaimer: This content is subject to change. The information is intended to inform and educate; it does not replace the medical evaluation, advice, diagnosis or treatment by a healthcare professional. www.nhpassist.com © 2014 NDAssist Inc. and/or its affiliates. All rights reserved.